Is an Identity Test needed for the content of all Containers?

Recommendation
27/28 May 2025
Supervision of the Pharmaceutical Quality System: Challenges and Opportunities
Chapter 5 of the EU-GMP Guidelines requires "appropriate procedures or measures to assure the identity of the contents of each container of starting material". Annex 8 to the EU-GMP Guidelines permits "to sample only a proportion of the containers where a validated procedure has been established to ensure that no single container of starting material has been incorrectly labelled." Nevertheless identity tests of starting materials are required.
And the FDA is also investigating the implementation of such procedures during their inspections. In a recent Warning Letter, the authority criticises a Chinese company for their inappropriate identity testing: "Your firm failed to conduct at least one test to verify the identity of each component of a drug product." The FDA not only cited the incomplete testing of incoming raw materials for their identity, strength, and other quality attributes. The firm also relied on the suppliers' certificate of analysis (COA) "without establishing the reliability of the suppliers' analyses through appropriate validation".
In addition, the company had no SOPs for quality unit operations like batch release, change control, complaint handling, supplier qualification or annual product reviews.
Related GMP News
21.05.2025More FDA Warning Letters citing Quality Oversight
21.05.2025New Version of GMP Auditors Handbook available
21.05.2025FDA: more unannounced Inspections also outside the US
14.05.2025How does FDA train and guide its Inspectors?
30.04.2025QP Declaration: New Q&As published
19.03.2025Root Cause Analysis: Again, problems discovered in GMP-Inspections